WO2016186977A1 - Novel fluoride prenatal dietary supplement - Google Patents
Novel fluoride prenatal dietary supplement Download PDFInfo
- Publication number
- WO2016186977A1 WO2016186977A1 PCT/US2016/032243 US2016032243W WO2016186977A1 WO 2016186977 A1 WO2016186977 A1 WO 2016186977A1 US 2016032243 W US2016032243 W US 2016032243W WO 2016186977 A1 WO2016186977 A1 WO 2016186977A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dietary supplement
- prenatal dietary
- supplement
- prenatal
- vitamin
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 161
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 title claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 49
- 239000013589 supplement Substances 0.000 claims description 143
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 44
- 239000011575 calcium Substances 0.000 claims description 40
- 229910052791 calcium Inorganic materials 0.000 claims description 40
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 38
- 244000005700 microbiome Species 0.000 claims description 31
- 210000003754 fetus Anatomy 0.000 claims description 21
- 230000035935 pregnancy Effects 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 19
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 19
- 229930003779 Vitamin B12 Natural products 0.000 claims description 18
- 235000019152 folic acid Nutrition 0.000 claims description 18
- 239000011724 folic acid Substances 0.000 claims description 18
- 235000019163 vitamin B12 Nutrition 0.000 claims description 18
- 239000011715 vitamin B12 Substances 0.000 claims description 18
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 17
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 17
- 229960000304 folic acid Drugs 0.000 claims description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 16
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 16
- 229930003571 Vitamin B5 Natural products 0.000 claims description 16
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 16
- 229960002079 calcium pantothenate Drugs 0.000 claims description 16
- 235000009492 vitamin B5 Nutrition 0.000 claims description 16
- 239000011675 vitamin B5 Substances 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 14
- 235000013361 beverage Nutrition 0.000 claims description 13
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 claims description 13
- 208000031729 Bacteremia Diseases 0.000 claims description 12
- 230000036446 length of gestation Effects 0.000 claims description 12
- 150000001768 cations Chemical class 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 10
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 10
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 10
- 239000010949 copper Substances 0.000 claims description 10
- 229910052802 copper Inorganic materials 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 10
- 210000002784 stomach Anatomy 0.000 claims description 10
- 239000011701 zinc Substances 0.000 claims description 10
- 229910052725 zinc Inorganic materials 0.000 claims description 10
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 9
- 230000001174 ascending effect Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 9
- 229940099596 manganese sulfate Drugs 0.000 claims description 9
- 239000011702 manganese sulphate Substances 0.000 claims description 9
- 235000007079 manganese sulphate Nutrition 0.000 claims description 9
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 9
- 229960002477 riboflavin Drugs 0.000 claims description 9
- 229930003471 Vitamin B2 Natural products 0.000 claims description 8
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 8
- 229960003512 nicotinic acid Drugs 0.000 claims description 8
- 235000019164 vitamin B2 Nutrition 0.000 claims description 8
- 239000011716 vitamin B2 Substances 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 7
- 229930003537 Vitamin B3 Natural products 0.000 claims description 7
- 229930003268 Vitamin C Natural products 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- 210000000214 mouth Anatomy 0.000 claims description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 7
- 210000005000 reproductive tract Anatomy 0.000 claims description 7
- 235000019160 vitamin B3 Nutrition 0.000 claims description 7
- 239000011708 vitamin B3 Substances 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 239000011775 sodium fluoride Substances 0.000 claims description 6
- 235000013024 sodium fluoride Nutrition 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 4
- 229960002799 stannous fluoride Drugs 0.000 claims description 4
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 4
- 235000014666 liquid concentrate Nutrition 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000003651 drinking water Substances 0.000 claims description 2
- 235000020188 drinking water Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 23
- 229940091249 fluoride supplement Drugs 0.000 description 48
- 150000001875 compounds Chemical class 0.000 description 23
- 241000894006 Bacteria Species 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 9
- -1 approximately 1 mg Chemical compound 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 206010036590 Premature baby Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 229960000414 sodium fluoride Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 208000002925 dental caries Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000032696 parturition Effects 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 241000589996 Campylobacter rectus Species 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 241001464887 Parvimonas micra Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 241000605861 Prevotella Species 0.000 description 2
- 241001135221 Prevotella intermedia Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241001135235 Tannerella forsythia Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 241000589892 Treponema denticola Species 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- XMQUEQJCYRFIQS-YFKPBYRVSA-N (2s)-2-amino-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)CC[C@H](N)C(O)=O XMQUEQJCYRFIQS-YFKPBYRVSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- 241000282596 Hylobatidae Species 0.000 description 1
- 241000283953 Lagomorpha Species 0.000 description 1
- 241000283986 Lepus Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000425347 Phyla <beetle> Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 206010073024 Preterm premature rupture of membranes Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091036333 Rapid DNA Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003761 Vitamin B9 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- ZXKXJHAOUFHNAS-UHFFFAOYSA-N fenfluramine hydrochloride Chemical compound [Cl-].CC[NH2+]C(C)CC1=CC=CC(C(F)(F)F)=C1 ZXKXJHAOUFHNAS-UHFFFAOYSA-N 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229940074371 monofluorophosphate Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021354 omega 7 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000021315 omega 9 monounsaturated fatty acids Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940005741 sunflower lecithin Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019159 vitamin B9 Nutrition 0.000 description 1
- 239000011727 vitamin B9 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- Fluoride is an important nutrition supplement that may affect long term dentition in children (Leverett et al., Randomized clinical trial of the effect of prenatal fluoride supplements in preventing dental caries. Caries Research 1997, 31(3), 174- 179).
- the Institute of Medicine has indicated the use of fluoride in pregnant women during the pre-emptive development of the teeth to reduce dental caries (Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride, Food and Nutrition Board, Institute of Medicine, 1997). Fluoride also has been previously associated with a reduction in preterm birth and increases in birth weight and length (neonatal ponderal index).
- the presently disclosed subject matter relates to a prenatal dietary supplement comprising a source of fluoride in an amount effective to provide at least about 3 mg of bioavailable fluoride.
- the source of fluoride is in an amount effective to provide between about 3 mg and 5 mg of bioavailable fluoride.
- the amount effective comprises between about 6 mg and 11 mg of the source of fluoride. In some embodiments, the amount effective comprises about 6.6 mg of the source of fluoride.
- the prenatal dietary supplement comprises decreased amounts of at least one cation that complexes with fluoride to reduce bioavailability of fluoride. In some embodiments, at least one cation is selected from the group consisting of calcium and magnesium. In some embodiments, the prenatal dietary supplement comprises a source of calcium that does not complex with fluoride to reduce the bioavailability of fluoride. In some embodiments, the source of calcium comprises calcium complexed to a vitamin. In some embodiments, the source of calcium comprises calcium complexed to vitamin B5. In some embodiments, the prenatal dietary supplement comprises about 10 mg of vitamin B5 and about 0.84 mg calcium as a complex.
- the source of fluoride is selected from the group consisting of sodium fluoride, sodium monofluorophosphate, stannous fluoride, and combinations thereof. In some embodiments, the source of fluoride comprises sodium fluoride.
- the prenatal dietary supplement further comprises between about 0 mg and about 2000 mg of vitamin C. In some embodiments, the prenatal dietary supplement further comprises about 200 mg of vitamin C. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 100 mg of vitamin Bi. In some embodiments, the prenatal dietary supplement further comprises about 10 mg of vitamin Bi. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 60 mg of vitamin B2. In some embodiments, the prenatal dietary supplement further comprises about 6 mg of vitamin B2. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 35 mg of vitamin B3. In some embodiments, the prenatal dietary supplement further comprises about 30 mg of vitamin B3.
- the prenatal dietary supplement further comprises between about 0 mg and 50 mg of vitamin Be. In some embodiments, the prenatal dietary supplement further comprises about 5 mg of vitamin Be. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 1 mg of folic acid. In some embodiments, the prenatal dietary supplement further comprises about 1 mg of folic acid. In some embodiments, the prenatal dietary supplement further comprises between about 0 ⁇ g and 150 ⁇ g of vitamin B12. In some embodiments, the prenatal dietary supplement further comprises about 15 ⁇ g of vitamin B12. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 100 mg of vitamin B5. In some embodiments, the prenatal dietary supplement further comprises about 10 mg of vitamin B5.
- the prenatal dietary supplement further comprises between about 0 mg and 69 mg of magnesium sulfate. In some embodiments, the prenatal dietary supplement further comprises about 6.9 mg of magnesium sulfate. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 40 mg of zinc. In some embodiments, the prenatal dietary supplement further comprises about 18.2 mg of zinc. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 10 mg of copper. In some embodiments, the prenatal dietary supplement further comprises about 0.8 mg of copper. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 13 mg of manganese sulfate. In some embodiments, the prenatal dietary supplement further comprising about 1.3 mg of manganese sulfate.
- the prenatal dietary supplement extends the length of gestation of a fetus when the supplement is administered to a pregnant woman during the second and third trimesters of pregnancy. In some embodiments, the prenatal dietary supplement changes the natural microbiome of a pregnant woman when administered to a pregnant woman during the second and third trimesters of pregnancy. In some embodiments, the supplement protects a pregnant woman and her fetus against transient bacteremia and ascending infection when the supplement is administered to the pregnant woman during the second and third trimesters of pregnancy.
- the prenatal dietary supplement is formulated for administration on an empty stomach or after drinking water. In some embodiments, the prenatal dietary supplement is formulated for administration at least 3 or at least 4 hours before, or at least 1 hour after, consumption of a food, beverage, or other supplement comprising calcium. In some embodiments, the supplement is formulated for administration at night. In some embodiments, the supplement is formulated for administration once during a 24 hour period. In some embodiments, the supplement is formulated for administration during the second and/or third trimester of pregnancy. In some embodiments, the prenatal dietary supplement comprises a form selected from the group consisting of a pill, tablet, capsule, liquid, liquid concentrate, and powder.
- the presently disclosed subject matter provides a kit comprising: (a) a prenatal dietary supplement according to any one of claims 1-45; and (b) a package insert or label with directions to administer the prenatal dietary supplement to a pregnant woman during the second and/or third trimesters of her pregnancy.
- the directions instruct the pregnant woman to take the prenatal dietary supplement on an empty stomach.
- the directions instruct the pregnant woman to take the prenatal dietary supplement at night.
- the presently disclosed subject matter provides a method for increasing the length of gestation of a fetus, the method comprising administering the presently disclosed prenatal dietary supplement, or presently disclosed kit, to the pregnant woman.
- the presently disclosed subject matter provides a method for changing the natural microbiome of a pregnant woman, the method comprising administering the presently disclosed prenatal dietary supplement, or presently disclosed kit, to the pregnant woman.
- the natural microbiome comprises a microbiome of the oral cavity, genital tract, and/or gastrointestinal tract of the pregnant woman.
- the pregnant woman is instructed not to drink milk or consume any other food, beverage, or other supplement comprising calcium at least 3 or at least 4 hours before taking, or at least 1 hour after taking, the prenatal dietary supplement.
- the prenatal dietary supplement is administered with plenty of water.
- the prenatal dietary supplement is administered at night.
- the prenatal dietary supplement is administered once every 24 hours.
- the prenatal dietary supplement is administered during the second and/or third trimester of pregnancy.
- the prenatal dietary supplement is administered from the 12th week of pregnancy until the pregnant woman gives birth.
- compositions, kits, and methods for administering a prenatal dietary supplement comprising fluoride to a pregnant woman It is disclosed herein that adequate intake of fluoride in a pregnant woman changes the natural microbiome of the pregnant woman, such as in her oral cavity, genital tract, and/or gastrointestinal tract. This change in the natural microbiome protects a pregnant woman against transient bacteremia and protects her fetus against ascending infection, thereby decreasing the chances of adverse perinatal outcomes.
- prenatal dietary supplement and specifically the fluoride in the supplement, has a beneficial effect on the natural microbiome of the maternal oral cavity, genital tract, and/or gastrointestinal tract, thereby protecting the mother against transient bacteremia and the fetus against ascending infection. This protection is believed to reduce adverse perinatal outcomes, such as prematurity and preterm premature rupture of membranes.
- premature birth and
- prenatality generally refers to the birth of a baby at less than about 37 weeks of gestational age.
- the presently disclosed prenatal dietary supplement is believed to extend the length of gestation of a fetus.
- the length of gestation increases by at least about 5%, 10%, 15%, 20%, 25%, 30%, or 40% as compared to the length of gestation of a fetus whose mother was not administered the presently disclosed prenatal dietary supplement using the presently disclosed methods.
- the length of gestation is increased from about 28 weeks to about 35 weeks.
- a prenatal dietary supplement refers to a supplement given to a pregnant woman to promote her health and the health of her fetus during her pregnancy.
- a prenatal dietary supplement is also generally referred to as a "prenatal vitamin”.
- the prenatal dietary supplement comprises a source of fluoride in an amount effective to provide about 3 mg of bioavailable fluoride.
- the source of fluoride is in an amount effective to provide between about 3 mg and 5 mg of bioavailable fluoride.
- the source of fluoride comprises between about 6 mg and 11 mg.
- the source of fluoride comprises about 6.6 mg.
- Na2P03F monofluorophosphate
- SnF2 stannous fluoride
- “decreased amounts” means that the supplement may contain an amount of cations that is negligible and would not be expected to significantly impact fluoride absorption. In some embodiments, “decreased amounts” means that the supplement contains an amount of cations that is less than 0.01 %, 1.0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% of a commercially available supplement. In some embodiments, “decreased amounts” means that the supplement contains an amount of the cation that reduces fluoride absorption by less than 1 %. In some embodiments, " As used herein, “poorly absorbed compounds” are those compounds which are not generally bioavailable.
- the supplement comprises decreased amounts of at least one cation that complexes with fluoride to reduce bioavailability of fluoride.
- at least one cation is selected from the group consisting of calcium and magnesium.
- the supplement has decreased amounts of calcium ions.
- the supplement contains an amount of calcium cations that is less than about 0.01 %, 0.05%, 0.10%, 0.25%, 0.30%, 0.33%, 0.40%, 0.50%, 0.66%, 0.75%, 0.80%, 0.90% or 1.0% of the total weight the prenatal dietary supplement of the presently disclosed subject matter.
- the supplement has decreased amounts of magnesium ions.
- the supplement contains an amount of magnesium cations that is less than 0.01 %, 0.05%, 0.10%, 0.25%, 0.30%, 0.33%, 0.40%, 0.50%, 0.66%, 0.75%, 0.80%, 0.90% or 1.0% of the total weight the prenatal dietary supplement of the presently disclosed subject matter.
- the supplement comprises a source of calcium that is in a form that does not complex with or bind to fluoride.
- the source of calcium may be bound to or complexed with a vitamin, such as vitamin B5.
- the calcium in the vitamin B5 - calcium complex does not bind to fluoride, thereby allowing the fluoride to still be bioavailable.
- the prenatal dietary supplement of the presently disclosed subject matter can optionally include a variety of vitamins and minerals which would be beneficial to the overall health and well being of a pregnant woman and her developing fetus.
- the supplement comprises vitamin C (also termed ascorbate and 2-oxo-L-threo-hexono-l ,4-lactone-2,3-enediol).
- the supplement comprises between about 0 mg and about 2000 mg of vitamin C. In some embodiments, the supplement comprises about 200 mg of vitamin C.
- the supplement comprises vitamin Bi (also termed thiamine and 3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2 -hydroxy ethyl)-4- methylthiazolium chloride).
- the supplement comprises between about 0 mg and 100 mg of vitamin Bi. In some embodiments, the supplement comprises between about 0 mg and about 30 mg of vitamin Bi. In some embodiments, the supplement comprises about 10 mg of vitamin Bi.
- the supplement comprises vitamin B3 (also termed niacin and pyridine-3-carboxylic acid). In some embodiments, the supplement comprises between about 0 mg and 40 mg of vitamin B3. In some embodiments, the supplement comprises about 30 mg of vitamin B3.
- the supplement comprises vitamin Be (for e.g., pyridoxine hydrochloride, pyridoxal 5 '-phosphate). In some embodiments, the supplement comprises between about 0 mg and 100 mg of vitamin Be. In some embodiments, the supplement comprises between about 0 mg and 20 mg of vitamin Be. In some embodiments, the supplement comprises about 5 mg of vitamin Be.
- vitamin Be for e.g., pyridoxine hydrochloride, pyridoxal 5 '-phosphate.
- the supplement comprises between about 0 mg and 100 mg of vitamin Be. In some embodiments, the supplement comprises between about 0 mg and 20 mg of vitamin Be. In some embodiments, the supplement comprises about 5 mg of vitamin Be.
- the supplement comprises folic acid (also termed folate, vitamin B9, and 2S)-2-[[4-[(2-amino-4-oxo-lH-pteridin-6- yl)methylamino] benzoyl] amino] pentanedioic acid).
- the supplement comprises between about 0 mg and 1 mg of folic acid.
- the supplement comprises 0.1 mg of folic acid.
- the supplement comprises 0.2 mg of folic acid.
- the supplement comprises 0.25 mg of folic acid.
- the supplement comprises 0.3 mg of folic acid.
- the supplement comprises 0.4 mg of folic acid.
- the supplement comprises vitamin B12 (also termed cobalamin and a-(5,6-dimethylbenzimidazolyl)cobamidcyanide). In some embodiments, the supplement comprises between about 0 ⁇ g and 150 ⁇ g of vitamin B12. In some embodiments, the supplement comprises between about 0 ⁇ g and 100 ⁇ g of vitamin B12. In some embodiments, the supplement comprises 10 ⁇ g of vitamin B12. In some embodiments, the supplement comprises 11 ⁇ g of vitamin B12. In some embodiments, the supplement comprises 12 ⁇ g of vitamin B12. In some
- the supplement comprises 13 ⁇ g of vitamin B12. In some embodiments, the supplement comprises 13 ⁇ g of vitamin B12.
- the supplement comprises vitamin B5 (also termed pantothenic acid and 3-[(2R)-2,4-dihydroxy-3,3-dimethylbutanamido]propanoic acid). In some embodiments, the supplement comprises between about 0 mg and 100 mg of vitamin B5. In some embodiments, the supplement comprises about 10 mg of vitamin B5. In some embodiments, the supplement comprises about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, or about 15 mg of Vitamin B5.
- the supplement comprises about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, or about 15 mg of Vitamin B5 and about 0.70 mg, about 0.71 mg, about 0.72 mg, about 0.73 mg, about 0.74 mg, about 0.75 mg, about 0.76 mg, about 0.77 mg, about 0.78 mg, about 0.79 mg, about 0.80 mg, about 0.81 mg, about 0.82 mg, about 0.83 mg, about 0.84 mg, about 0.85 mg, about 0.86 mg, about 0.87 mg, about 0.88 mg, about 0.89 mg, about 0.90 mg, about 0.91 mg, about 0.92 mg, about 0.93 mg, about 0.94 mg or about 0.95 mg calcium as a complex. In some embodiments, the supplement comprises about 10 mg of vitamin B5 and about 0.84 mg calcium as a complex.
- the supplement comprises magnesium sulfate
- the supplement comprises between about 0 mg and 350 mg of magnesium sulfate.
- the supplement comprises about 6.0 mg, about 6.1 mg, about 6.2 mg, about 6.3 mg, about 6.4 mg about 6.5 mg, about 6.6 mg, about 6.7 mg, about 6.8 mg, about 6.9 mg, about 7.0 mg, about 7.1 mg, about 7.2 mg, about 7.3 mg, about 7.4 mg about 7.5 mg, about 7.6 mg, about 7.7 mg, about 7.8 mg, about 7.9 mg, or about 8.0 mg of magnesium sulfate.
- the supplement comprises about 6.9 mg of magnesium sulfate.
- the supplement comprises zinc, such as zinc sulfate. In some embodiments, the supplement comprises between about 0 mg and 40 mg of zinc. In some embodiments, the supplement comprises between about 0 mg and 25 mg of zinc. In some embodiments, the supplement comprises about 17.0 mg, about
- the supplement comprises about 18.2 mg of zinc.
- the supplement comprises copper, such as cupric sulfate. In some embodiments, the supplement comprises between about 0 mg and 10 mg of copper.
- the supplement comprises between about 0 mg and 2 mg of copper. In some embodiments, the supplement comprises about 0.1 mg, about 0.2 mg, about 0.3 mg, about 10.4 mg about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, or about 1.9 mg of copper. In some embodiments, the supplement comprises about 0.8 mg of copper.
- the supplement comprises manganese sulfate
- the supplement comprises between about 0 mg and 1 1 mg of manganese sulfate. In some embodiments, the supplement comprises between about 0 mg and 5 mg of manganese sulfate. In some embodiments, the supplement comprises about 0.1 mg, about 0.2 mg, about 0.3 mg, about 10.4 mg about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, or about 2.0 mg of manganese sulfate. In some embodiments, the supplement comprises about 1.3 mg of manganese sulfate.
- the prenatal dietary supplement of the presently disclosed subject matter is formulated to maximize bioavailability of fluoride.
- the supplement is formulated for administration on an empty stomach.
- the supplement is formulated for administration to a subject that has previously ingested a liquid, such as water.
- the supplement is formulated for administration after the subject drinks up to about 4 cups of water prior to taking the supplement.
- the supplement is formulated for administration along with about 0.5 cups (4 ounces) of water.
- the supplement is formulated for administration along with about 5 ounces of water.
- the supplement is formulated for administration along with about 6 ounces of water.
- the supplement is formulated for administration along with about 7 ounces of water. In some embodiments, the supplement is formulated for administration along with about 8 ounces of water. In some embodiments, the supplement is formulated for administration along with about 10 ounces, about 12 ounces, about 14 ounces, about 16 ounces, about 20 ounces, about 24 ounces, or more of water. In some embodiments, the supplement is formulated for administration at least 3 or at least 4 hours before consumption of a food, beverage, or other supplement comprising calcium. In some embodiments, the supplement is formulated for administration at least 1 hour after consumption of a food, beverage, or other supplement comprising calcium.
- microbiome refers to the totality of microbes, such as bacteria, fungi, and protists, and their genetic elements or genomes in a defined environment, e.g. within the oral cavity, genital tract, and/or gastrointestinal tract of a host.
- naturally microbiome refers to the microbiome of a subject before administration of a presently disclosed supplement.
- Natural microbiome may also refer to the microbiome of a subject that is not given a presently disclosed supplement.
- Microbiomes can be investigated or monitored using rapid DNA sequencing techniques, such as by sequencing 16S rRNA. In some embodiments, in order to sequence microbiome DNA (target DNA), it is desirable to remove contaminating mammalian genomic DNA (non-target DNA) from a DNA mixture obtained from a biological sample.
- the microbiome is monitored by assaying the mRNA composition of a biological sample.
- microfloral pattern or signature for the subj ect being tested, e.g. for the region of the oral cavity, genital tract, and/or gastrointestinal tract that has been sampled, or for the type of sample that is analyzed.
- the overall partem of microflora is assessed, i.e. not only are particular taxa identified, but the percentage of each constituent taxon is taken in account, in comparison to all taxa that are detected and, usually, or optionally, to each other.
- a "pie chart" format may be used to depict a microfloral signature; or the relationships may be expressed numerically or graphically as ratios or percentages of all taxa detected, etc.
- the data may be manipulated so that only selected subsets of the taxa are considered (e.g. key indicators with strong positive correlations). Data may be expressed, e.g.
- a nonparametric multivariate test such as Metastats, Analysis of Similarity, Principle Component Analysis, Non-Parametric MANOVA (Kruskal-Wallace) etc. can be used to associate a change in microbiome from a subject before the prenatal dietary supplement is administered to the microbiome of the subject after the prenatal dietary supplement has been administered.
- microbiota composition there are changes in the microbiota composition. In some embodiments, there are changes in the total number of bacteria in the microbiome. In some embodiments, there are changes in both the microbiota composition and the total number of bacteria in the microbiome. In some embodiments,
- Campylobacter rectus Tannerella forsythensis, Treponema denticola, Fusobacterium nucleatum, Peptostreptococcus micros, Prevotella intermedia, and Prevotella nigrescence.
- Porphyromonas gingivalis there are changes in the total number of Campylobacter rectus. In some embodiments, there are changes in the total number of Tannerella forsythensis. In some embodiments, there are changes in the total number of Treponema denticola. In some embodiments, there are changes in the total number of Fusobacterium nucleatum. In some embodiments, there are changes in the total number of Peptostreptococcus micros. In some embodiments, there are changes in the total number of Prevotella intermedia. In some embodiments, there are changes in the total number of Campylobacter rectus. In some embodiments, there are changes in the total number of Tannerella forsythensis. In some embodiments, there are changes in the total number of Treponema denticola. In some embodiments, there are changes in the total number of Fusobacterium nucleatum. In some embodiments, there are changes in the total number of Peptostreptoc
- the term "anaerobic bacteria” refers to bacteria that do not require normal levels of oxygen for survival and/or growth.
- the term “gram-negative bacteria” refer to those classes of bacteria that do not retain the crystal violet stain.
- the term “bacteremia” refers to the presence of bacteria in the blood.
- Transient bacteremia refers to bacteremia that is not persistent. Bacteremia in a pregnant woman can affect the woman as well as the fetus.
- an "ascending infection” is an infection in which the organism causing the infection contaminates the amniotic fluid.
- compositions, kits and methods of the presently disclosed subject matter include the pharmaceutically acceptable salts of the compounds described above.
- pharmaceutically acceptable salts is meant to include salts of active compounds, which are prepared with relatively nontoxic acids or bases, depending on the particular substituent moieties found on the compounds described herein.
- agents for use within the methods of the presently disclosed subj ect matter can exist in unsolvated forms, as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present disclosure. Certain agents for use within the methods of the presently disclosed subject matter may exist in multiple crystalline or amorphous forms.
- the presently disclosed prenatal dietary supplement can be administered using a variety of methods known in the art.
- the administering can be carried out by, for example, intravenous infusion; inj ection by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes; or topical or oral application.
- the presently disclosed supplements are administered orally.
- the prenatal dietary supplement is in the form of a tablet. In some embodiments, the prenatal dietary supplement is in the form of a pill. In some embodiments, the prenatal dietary supplement is in the form of a capsule. In some embodiments, the prenatal dietary supplement is in the form of a liquid or liquid concentrate. In some embodiments, the prenatal dietary supplement is in the form of a powder.
- Agents for use within the compositions, kits, and methods of the presently disclosed subject matter can be manufactured in a manner known in the art, e.g. by means of conventional mixing, dissolving, granulating, dragee-making, levitating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- agents within the compositions, kits, and methods of the presently disclosed subject matter for oral use can be obtained through combination of active compounds with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients include, but are not limited to, carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethyl cellulose; and gums including arabic and tragacanth; and proteins, such as gelatin and collagen; and polyvinylpyrrolidone (PVP:povidone).
- disintegrating or solubilizing agents such as cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, also can be added to the compositions.
- Dragee cores are provided with suitable coatings, such as concentrated sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol (PEG), and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, e.g., dosage, or different combinations of active compound doses.
- compositions suitable for oral administration include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, e.g., a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain active ingredients admixed with a filler or binder, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers.
- the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols (PEGs), with or without stabilizers.
- Stabilizers can be added as warranted.
- the agents for use within the compositions, kits, and methods of the presently disclosed subject matter can be administered by rechargeable or biodegradable devices.
- rechargeable or biodegradable devices For example, a variety of slow-release polymeric devices have been developed and tested in vivo for the controlled delivery of drugs, including proteinacious biopharmaceuticals. Suitable examples of sustained release
- preparations include semipermeable polymer matrices in the form of shaped articles, e.g., films or microcapsules.
- Sustained release matrices include polyesters, hydrogels, polylactides (U.S. Patent No. 3,773,919; EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al, Biopolymers 22:547, 1983), poly (2- hydroxyethyl-methacrylate) (Langer et al, J. Biomed. Mater. Res. 15: 167, 1981 ;
- Sustained release compositions also include liposomally entrapped compounds, which can be prepared by methods known per se (Epstein et al., Proc. Natl. Acad. Sci. U.S.A. 82:3688, 1985; Hwang et al., Proc. Natl. Acad. Sci. U.S.A. 77:4030, 1980; U.S. Patent Nos. 4,485,045 and 4,544,545; and EP 102,324 A).
- the liposomes are of the small (about 200-800 Angstroms) unilamelar type in which the lipid content is greater than about 30 mol % cholesterol, the selected proportion being adjusted for the optimal therapy.
- Such materials can comprise an implant, for example, for sustained release of the presently disclosed compounds, which, in some embodiments, can be implanted at a particular, pre-determined target site.
- Pharmaceutical compositions for parenteral administration include aqueous solutions of active compounds.
- the presently disclosed pharmaceutical compositions can be formulated in aqueous solutions, for example, in some embodiments, in physiologically compatible buffers, such as Hank's solution, Ringer' solution, or physiologically buffered saline.
- Aqueous injection suspensions can contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
- suspensions of the active compounds or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
- the suspension also can contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
- penetrants appropriate to the particular barrier to be permeated are used in the formulation.
- penetrants are generally known in the art.
- agents for use within the methods of the presently disclosed subject matter also can be formulated by methods known to those of skill in the art, and may include, for example, but not limited to, examples of solubilizing, diluting, or dispersing substances such as, saline, preservatives, such as benzyl alcohol, absorption promoters, and fluorocarbons.
- fragrances, opacifiers, antioxidants, gelling agents, stabilizers, surfactants, emollients, coloring agents, preservatives, buffering agents, and the like can be present.
- the pH of the presently disclosed topical composition can be adjusted to a physiologically acceptable range of from about 6.0 to about 9.0 by adding buffering agents thereto such that the composition is physiologically compatible with a subject's skin.
- agents for use within the methods of the presently disclosed subject matter which may be used in a suitable hydrated form, and/or the pharmaceutical compositions are formulated into pharmaceutically acceptable dosage forms such as described below or by other conventional methods known to those of skill in the art.
- kits for practicing the methods of the presently disclosed subject matter.
- a presently disclosed kit contains some or all of the components, reagents, supplies, and the like to practice a method according to the presently disclosed subject matter.
- the term "kit” refers to any intended any article of manufacture (e.g., a package or a container) comprising at least one prenatal dietary supplement and a set of particular instructions for practicing the methods of the presently disclosed subject matter.
- the kit can be packaged in a divided or undivided container, such as a carton, bottle, ampule, tube, etc.
- the presently disclosed supplements can be packaged in dried, lyophilized, or liquid form. In some embodiments, the supplements are packaged in pill, capsule, or tablet form.
- the presently disclosed subject matter provides a kit comprising: (a) a prenatal dietary supplement described herein; and (b) a package insert or label with directions to administer the prenatal dietary supplement to a pregnant woman during the second and/or third trimesters of her pregnancy.
- the directions instruct the pregnant woman to take the prenatal dietary supplement on an empty stomach or after drinking a liquid, such as water. In some embodiments, the directions instruct the pregnant woman to take the prenatal dietary supplement at night.
- the presently disclosed methods change the natural microbiome of a pregnant woman, the method comprising administering a prenatal dietary supplement of presently disclosed subject matter to the pregnant woman.
- the presently disclosed methods protect the pregnant woman and her fetus against transient bacteremia and/or ascending infection.
- the presently disclosed methods increase the length of gestation of a fetus.
- the prenatal dietary supplement disclosed herein may increase the length of gestation of a fetus in a pregnant woman by at least 5%, at least 10%, at least 15%, at least 20%, or at least 25% compared to the length of gestation of the fetus in the pregnant woman in the absence of supplementation with the supplement.
- the natural microbiome comprises a microbiome of the oral cavity, genital tract, and/or gastrointestinal tract of the pregnant woman.
- the methods comprise selecting a pregnant woman whose fetus is thought to need an extended length of gestation.
- the selection of a pregnant woman may be based on a variety of factors, such as a family history of relatives giving birth to a premature baby or giving birth to a baby before the due date even though it may be mature, and/or the pregnant woman herself giving birth previously to a baby born prematurely or born before the baby's due date.
- the length of the gestation is expected to be increased by at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, a week, two weeks, three weeks, a month, two months or more.
- the fluoride in the prenatal dietary supplement described herein aids in changing the natural microbiome of a pregnant woman.
- the prenatal dietary supplement does not comprise compounds that reduce the bioavailability of fluoride.
- the supplement is administered in the absence of other sources of compounds that reduce the bioavailability of fluoride, such as calcium.
- the prenatal dietary supplement is administered when the pregnant woman has an empty stomach.
- the prenatal dietary supplement is administered when the pregnant woman has previously ingested a liquid, such as water.
- the prenatal dietary supplement is administered with plenty of water.
- plenty of water comprises consuming at least 8 OZ, at least 16 OZ, at least 24 OZ, at least 32 OZ, at least 48 OZ, or at least 64 OZ between about 120 minutes, 90 minutes, 60 minutes, 45 minutes, 30 minutes, or 15 minutes before and after taking the prenatal dietary supplement.
- the supplement is formulated for administration after the pregnant woman drinks up to about 4 cups of water prior to taking the supplement.
- the pregnant woman is administered the supplement along with about 0.5 cups (4 ounces) of water.
- the pregnant woman is administered the supplement at least 3 or at least 4 hours before the pregnant woman consumes a food, beverage, or other supplement comprising calcium. In some embodiments, the pregnant woman is administered the supplement at least 1 hour after the pregnant woman consumes a food, beverage, or other supplement comprising calcium. In some embodiments, the prenatal dietary supplement is administered at least approximately 6 hours before or after the pregnant woman consumes a food, beverage, or other supplement comprising calcium. In some embodiments, the pregnant woman is instructed not to drink milk or consume any other food, beverage, or other supplement comprising calcium at least 3 or at least 4 hours before taking, or at least 1 hour after taking, the prenatal dietary supplement.
- the prenatal dietary supplement is administered at night when other sources of calcium are not taken. In some embodiments, the prenatal dietary supplement is administered once every 24 hours. In some embodiments, the prenatal dietary supplement is administered during the second and/or third trimester of pregnancy. In some embodiments, the prenatal dietary supplement is administered (e.g., once daily at nighttime on an empty stomach with plenty of water) from the 12th week of pregnancy until the pregnant woman gives birth.
- the prenatal dietary supplement is administered once every 24 hours at nighttime with plenty of water when other sources of calcium are not taken.
- a "subject” can include a female human subject for medical purposes, such as for the treatment of an existing disease, disorder, condition or the prophylactic treatment for preventing the onset of a disease, disorder, or condition or a female animal subject for medical, veterinary purposes, or developmental purposes.
- Suitable animal subjects include mammals including, but not limited to, primates, e.g., humans, monkeys, apes, gibbons, chimpanzees, orangutans, macaques and the like; bovines, e.g., cattle, oxen, and the like; ovines, e.g., sheep and the like; caprines, e.g., goats and the like; porcines, e.g., pigs, hogs, and the like; equines, e.g., horses, donkeys, zebras, and the like; felines, including wild and domestic cats; canines, including dogs; lagomorphs, including rabbits, hares, and the like; and rodents, including mice, rats, guinea pigs, and the like.
- An animal may be a transgenic animal.
- the term "about,” when referring to a value can be meant to encompass variations of, in some embodiments, ⁇ 100% in some embodiments ⁇ 50%, in some embodiments ⁇ 20%, in some embodiments ⁇ 10%, in some embodiments ⁇ 5%, in some embodiments ⁇ 1 %, in some embodiments ⁇ 0.5%, and in some embodiments ⁇ 0.1 % from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Pediatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The presently disclosed subject matter provides compositions, kits, and methods for administering a prenatal dietary supplement comprising at least about 3 mg of bioavailable fluoride to a pregnant woman.
Description
NOVEL FLUORIDE PRENATAL DIETARY SUPPLEMENT REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional Patent Application No. 62/162, 198 filed on May 15, 2015, which is hereby incorporated by reference for all purposes as if fully set forth herein.
BACKGROUND OF THE INVENTION
Fluoride is an important nutrition supplement that may affect long term dentition in children (Leverett et al., Randomized clinical trial of the effect of prenatal fluoride supplements in preventing dental caries. Caries Research 1997, 31(3), 174- 179). The Institute of Medicine has indicated the use of fluoride in pregnant women during the pre-emptive development of the teeth to reduce dental caries (Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride, Food and Nutrition Board, Institute of Medicine, 1997). Fluoride also has been previously associated with a reduction in preterm birth and increases in birth weight and length (neonatal ponderal index).
Currently, the existing prenatal dietary supplements on the market contain a low dose of fluoride, such as approximately 1 mg, or do not contain fluoride at all.
SUMMARY OF THE INVENTION
In one aspect, the presently disclosed subject matter relates to a prenatal dietary supplement comprising a source of fluoride in an amount effective to provide at least about 3 mg of bioavailable fluoride. In some embodiments, the source of fluoride is in an amount effective to provide between about 3 mg and 5 mg of bioavailable fluoride. In some embodiments, the amount effective comprises between about 6 mg and 11 mg of the source of fluoride. In some embodiments, the amount effective comprises about 6.6 mg of the source of fluoride.
In some embodiments, the prenatal dietary supplement comprises decreased amounts of at least one cation that complexes with fluoride to reduce bioavailability of fluoride. In some embodiments, at least one cation is selected from the group
consisting of calcium and magnesium. In some embodiments, the prenatal dietary supplement comprises a source of calcium that does not complex with fluoride to reduce the bioavailability of fluoride. In some embodiments, the source of calcium comprises calcium complexed to a vitamin. In some embodiments, the source of calcium comprises calcium complexed to vitamin B5. In some embodiments, the prenatal dietary supplement comprises about 10 mg of vitamin B5 and about 0.84 mg calcium as a complex.
In some embodiments, the source of fluoride is selected from the group consisting of sodium fluoride, sodium monofluorophosphate, stannous fluoride, and combinations thereof. In some embodiments, the source of fluoride comprises sodium fluoride.
In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and about 2000 mg of vitamin C. In some embodiments, the prenatal dietary supplement further comprises about 200 mg of vitamin C. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 100 mg of vitamin Bi. In some embodiments, the prenatal dietary supplement further comprises about 10 mg of vitamin Bi. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 60 mg of vitamin B2. In some embodiments, the prenatal dietary supplement further comprises about 6 mg of vitamin B2. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 35 mg of vitamin B3. In some embodiments, the prenatal dietary supplement further comprises about 30 mg of vitamin B3. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 50 mg of vitamin Be. In some embodiments, the prenatal dietary supplement further comprises about 5 mg of vitamin Be. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 1 mg of folic acid. In some embodiments, the prenatal dietary supplement further comprises about 1 mg of folic acid. In some embodiments, the prenatal dietary supplement further comprises between about 0 μg and 150 μg of vitamin B12. In some embodiments, the prenatal dietary supplement further comprises about 15 μg of vitamin B12. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 100 mg of vitamin B5. In some embodiments, the prenatal dietary supplement
further comprises about 10 mg of vitamin B5. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 69 mg of magnesium sulfate. In some embodiments, the prenatal dietary supplement further comprises about 6.9 mg of magnesium sulfate. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 40 mg of zinc. In some embodiments, the prenatal dietary supplement further comprises about 18.2 mg of zinc. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 10 mg of copper. In some embodiments, the prenatal dietary supplement further comprises about 0.8 mg of copper. In some embodiments, the prenatal dietary supplement further comprises between about 0 mg and 13 mg of manganese sulfate. In some embodiments, the prenatal dietary supplement further comprising about 1.3 mg of manganese sulfate.
In some embodiments, the prenatal dietary supplement extends the length of gestation of a fetus when the supplement is administered to a pregnant woman during the second and third trimesters of pregnancy. In some embodiments, the prenatal dietary supplement changes the natural microbiome of a pregnant woman when administered to a pregnant woman during the second and third trimesters of pregnancy. In some embodiments, the supplement protects a pregnant woman and her fetus against transient bacteremia and ascending infection when the supplement is administered to the pregnant woman during the second and third trimesters of pregnancy.
In some embodiments, the prenatal dietary supplement is formulated for administration on an empty stomach or after drinking water. In some embodiments, the prenatal dietary supplement is formulated for administration at least 3 or at least 4 hours before, or at least 1 hour after, consumption of a food, beverage, or other supplement comprising calcium. In some embodiments, the supplement is formulated for administration at night. In some embodiments, the supplement is formulated for administration once during a 24 hour period. In some embodiments, the supplement is formulated for administration during the second and/or third trimester of pregnancy. In some embodiments, the prenatal dietary supplement comprises a form selected from the group consisting of a pill, tablet, capsule, liquid, liquid concentrate, and powder.
In other aspects, the presently disclosed subject matter provides a kit comprising: (a) a prenatal dietary supplement according to any one of claims 1-45; and (b) a package insert or label with directions to administer the prenatal dietary supplement to a pregnant woman during the second and/or third trimesters of her pregnancy. In some embodiments, the directions instruct the pregnant woman to take the prenatal dietary supplement on an empty stomach. In some embodiments, the directions instruct the pregnant woman to take the prenatal dietary supplement at night.
In some aspects, the presently disclosed subject matter provides a method for increasing the length of gestation of a fetus, the method comprising administering the presently disclosed prenatal dietary supplement, or presently disclosed kit, to the pregnant woman.
In certain aspects, the presently disclosed subject matter provides a method for changing the natural microbiome of a pregnant woman, the method comprising administering the presently disclosed prenatal dietary supplement, or presently disclosed kit, to the pregnant woman. In some embodiments, the natural microbiome comprises a microbiome of the oral cavity, genital tract, and/or gastrointestinal tract of the pregnant woman.
In other aspects, the presently disclosed subject matter provides a method for protecting a pregnant woman and her fetus against transient bacteremia and/or ascending infection, the method comprising administering the presently disclosed prenatal dietary supplement, or presently disclosed kit, to the pregnant woman. In some embodiments, the prenatal dietary supplement is administered when the pregnant woman has an empty stomach or has previously ingested water. In some embodiments, the prenatal dietary supplement is administered at least 3 or at least 4 hours before, or at least 1 hour after, the pregnant woman consumes a food, beverage, or other supplement comprising calcium. In some embodiments, the pregnant woman is instructed not to drink milk or consume any other food, beverage, or other supplement comprising calcium at least 3 or at least 4 hours before taking, or at least 1 hour after taking, the prenatal dietary supplement. In some embodiments, the prenatal dietary supplement is administered with plenty of water. In some embodiments, the prenatal dietary supplement is administered at night. In some
embodiments, the prenatal dietary supplement is administered once every 24 hours. In some embodiments, the prenatal dietary supplement is administered during the second and/or third trimester of pregnancy. In some embodiments, the prenatal dietary supplement is administered from the 12th week of pregnancy until the pregnant woman gives birth.
Certain aspects of the presently disclosed subject matter having been stated hereinabove, which are addressed in whole or in part by the presently disclosed subject matter, other aspects will become evident as the description proceeds when taken in connection with the accompanying Examples and Figures as best described herein below.
DETAILED DESCRIPTION OF THE INVENTION
The presently disclosed subject matter now will be described more fully hereinafter. Like numbers refer to like elements throughout. The presently disclosed subject matter may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. Indeed, many modifications and other embodiments of the presently disclosed subject matter set forth herein will come to mind to one skilled in the art to which the presently disclosed subject matter pertains having the benefit of the teachings presented in the foregoing descriptions. Therefore, it is to be understood that the presently disclosed subject matter is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims.
The presently disclosed subject matter provides compositions, kits, and methods for administering a prenatal dietary supplement comprising fluoride to a pregnant woman. It is disclosed herein that adequate intake of fluoride in a pregnant woman changes the natural microbiome of the pregnant woman, such as in her oral cavity, genital tract, and/or gastrointestinal tract. This change in the natural microbiome protects a pregnant woman against transient bacteremia and protects her fetus against ascending infection, thereby decreasing the chances of adverse perinatal outcomes.
PRENATAL DIETARY SUPPLEMENT COMPOSITIONS
The presently disclosed prenatal dietary supplement, and specifically the fluoride in the supplement, has a beneficial effect on the natural microbiome of the maternal oral cavity, genital tract, and/or gastrointestinal tract, thereby protecting the mother against transient bacteremia and the fetus against ascending infection. This protection is believed to reduce adverse perinatal outcomes, such as prematurity and preterm premature rupture of membranes. The terms "premature birth" and
"prematurity" generally refers to the birth of a baby at less than about 37 weeks of gestational age. In some embodiments, the presently disclosed prenatal dietary supplement is believed to extend the length of gestation of a fetus. In some embodiments, the length of gestation increases by at least about 5%, 10%, 15%, 20%, 25%, 30%, or 40% as compared to the length of gestation of a fetus whose mother was not administered the presently disclosed prenatal dietary supplement using the presently disclosed methods. In some embodiments, the length of gestation is increased from about 28 weeks to about 35 weeks.
A "prenatal dietary supplement" as used herein refers to a supplement given to a pregnant woman to promote her health and the health of her fetus during her pregnancy. A prenatal dietary supplement is also generally referred to as a "prenatal vitamin". In some embodiments, the prenatal dietary supplement comprises a source of fluoride in an amount effective to provide about 3 mg of bioavailable fluoride. In some embodiments, the source of fluoride is in an amount effective to provide between about 3 mg and 5 mg of bioavailable fluoride. In some embodiments, the source of fluoride comprises between about 6 mg and 11 mg. In some embodiments, the source of fluoride comprises about 6.6 mg.
The source of fluoride found in the prenatal dietary supplement is in a form that can be made bioavailable, such as sodium fluoride (NaF), sodium
monofluorophosphate (Na2P03F), and stannous fluoride (SnF2). The term
"bioavailable" as used herein refers to the dose of a compound that reaches systemic circulation after being administered. In some embodiments, the fluoride is in the form of sodium fluoride. In some embodiments, the fluoride is in the form of sodium monofluorophosphate. In some embodiments, the fluoride is in the form of stannous
fluoride. In some embodiments, the source of fluoride is selected from the group consisting of sodium fluoride, sodium monofluorophosphate, stannous fluoride, and combinations thereof. In some embodiments, the fluoride is not in the form of calcium fluoride, which has been found to be generally not bioavailable.
The prenatal dietary supplement of the presently disclosed subj ect matter is formulated to have decreased amounts of cations with which fluoride may complex to form insoluble compounds that limit fluoride absorbability and bioavailability. As used herein, the term "cation" refers to positively-charged ions such as calcium (Ca2+), magnesium (Mg2+), potassium (K+), sodium (Na+) hydrogen (H+), aluminum (Al +), iron (Fe2+), manganese (Mn2+), zinc (Zn2+) and copper (Cu2+). As used herein, "decreased amounts" means that the supplement may contain an amount of cations that is negligible and would not be expected to significantly impact fluoride absorption. In some embodiments, "decreased amounts" means that the supplement contains an amount of cations that is less than 0.01 %, 1.0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, or 80% of a commercially available supplement. In some embodiments, "decreased amounts" means that the supplement contains an amount of the cation that reduces fluoride absorption by less than 1 %. In some embodiments, " As used herein, "poorly absorbed compounds" are those compounds which are not generally bioavailable. In some embodiments, the supplement comprises decreased amounts of at least one cation that complexes with fluoride to reduce bioavailability of fluoride. In some embodiments, at least one cation is selected from the group consisting of calcium and magnesium. In some embodiments, the supplement has decreased amounts of calcium ions. In some embodiments, the supplement contains an amount of calcium cations that is less than about 0.01 %, 0.05%, 0.10%, 0.25%, 0.30%, 0.33%, 0.40%, 0.50%, 0.66%, 0.75%, 0.80%, 0.90% or 1.0% of the total weight the prenatal dietary supplement of the presently disclosed subject matter. In some embodiments, the supplement has decreased amounts of magnesium ions. In some embodiments, the supplement contains an amount of magnesium cations that is less than 0.01 %, 0.05%, 0.10%, 0.25%, 0.30%, 0.33%, 0.40%, 0.50%, 0.66%, 0.75%, 0.80%, 0.90% or 1.0% of the total weight the prenatal dietary supplement of the presently disclosed subject matter.
In some embodiments, the supplement comprises a source of calcium that is in a form that does not complex with or bind to fluoride. For example, the source of calcium may be bound to or complexed with a vitamin, such as vitamin B5. In this case, the calcium in the vitamin B5 - calcium complex does not bind to fluoride, thereby allowing the fluoride to still be bioavailable.
It should be appreciated that the prenatal dietary supplement of the presently disclosed subject matter can optionally include a variety of vitamins and minerals which would be beneficial to the overall health and well being of a pregnant woman and her developing fetus. In some embodiments, the supplement comprises vitamin C (also termed ascorbate and 2-oxo-L-threo-hexono-l ,4-lactone-2,3-enediol). In some embodiments, the supplement comprises between about 0 mg and about 2000 mg of vitamin C. In some embodiments, the supplement comprises about 200 mg of vitamin C.
In some embodiments, the supplement comprises vitamin Bi (also termed thiamine and 3-((4-Amino-2-methyl-5-pyrimidinyl)methyl)-5-(2 -hydroxy ethyl)-4- methylthiazolium chloride). In some embodiments, the supplement comprises between about 0 mg and 100 mg of vitamin Bi. In some embodiments, the supplement comprises between about 0 mg and about 30 mg of vitamin Bi. In some embodiments, the supplement comprises about 10 mg of vitamin Bi.
In some embodiments, the supplement comprises vitamin B2 (also termed riboflavin and 7,8-dimethyl-10-[(2S,3S,4R)-2,3,4,5- tetrahydroxypentyl]benzo[g]pteridine-2,4-dione). In some embodiments, the supplement comprises between about 0 mg and 60 mg of vitamin B2. In some embodiments, the supplement comprises between about 0 mg and 35 mg of vitamin B2. In some embodiments, the supplement comprises about 6 mg of vitamin B2.
In some embodiments, the supplement comprises vitamin B3 (also termed niacin and pyridine-3-carboxylic acid). In some embodiments, the supplement comprises between about 0 mg and 40 mg of vitamin B3. In some embodiments, the supplement comprises about 30 mg of vitamin B3.
In some embodiments, the supplement comprises vitamin Be (for e.g., pyridoxine hydrochloride, pyridoxal 5 '-phosphate). In some embodiments, the supplement comprises between about 0 mg and 100 mg of vitamin Be. In some
embodiments, the supplement comprises between about 0 mg and 20 mg of vitamin Be. In some embodiments, the supplement comprises about 5 mg of vitamin Be.
In some embodiments, the supplement comprises folic acid (also termed folate, vitamin B9, and 2S)-2-[[4-[(2-amino-4-oxo-lH-pteridin-6- yl)methylamino] benzoyl] amino] pentanedioic acid). In some embodiments, the supplement comprises between about 0 mg and 1 mg of folic acid. In some embodiments, the supplement comprises 0.1 mg of folic acid. In some embodiments, the supplement comprises 0.2 mg of folic acid. In some embodiments, the supplement comprises 0.25 mg of folic acid. In some embodiments, the supplement comprises 0.3 mg of folic acid. In some embodiments, the supplement comprises 0.4 mg of folic acid. In some embodiments, the supplement comprises 0.5 mg of folic acid. In some embodiments, the supplement comprises 0.6 mg of folic acid. In some embodiments, the supplement comprises 0.7 mg of folic acid. In some embodiments, the supplement comprises 0.8 mg of folic acid. In some embodiments, the supplement comprises 0.9 mg of folic acid. In some embodiments, the supplement comprises about 1 mg of folic acid.
In some embodiments, the supplement comprises vitamin B12 (also termed cobalamin and a-(5,6-dimethylbenzimidazolyl)cobamidcyanide). In some embodiments, the supplement comprises between about 0 μg and 150 μg of vitamin B12. In some embodiments, the supplement comprises between about 0 μg and 100 μg of vitamin B12. In some embodiments, the supplement comprises 10 μg of vitamin B12. In some embodiments, the supplement comprises 11 μg of vitamin B12. In some embodiments, the supplement comprises 12 μg of vitamin B12. In some
embodiments, the supplement comprises 13 μg of vitamin B12. In some
embodiments, the supplement comprises 14 μg of vitamin B12. In some embodiments, the supplement comprises about 15 μg of vitamin B12. In some embodiments, the supplement comprises 16 μg of vitamin B12. In some embodiments, the supplement comprises 17 μg of vitamin B12. In some embodiments, the supplement comprises 18 μg of vitamin B12. In some embodiments, the supplement comprises 19 μg of vitamin B12. In some embodiments, the supplement comprises 20 μg of vitamin B12.
In some embodiments, the supplement comprises vitamin B5 (also termed pantothenic acid and 3-[(2R)-2,4-dihydroxy-3,3-dimethylbutanamido]propanoic acid).
In some embodiments, the supplement comprises between about 0 mg and 100 mg of vitamin B5. In some embodiments, the supplement comprises about 10 mg of vitamin B5. In some embodiments, the supplement comprises about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, or about 15 mg of Vitamin B5. In some embodiments, the supplement comprises about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, or about 15 mg of Vitamin B5 and about 0.70 mg, about 0.71 mg, about 0.72 mg, about 0.73 mg, about 0.74 mg, about 0.75 mg, about 0.76 mg, about 0.77 mg, about 0.78 mg, about 0.79 mg, about 0.80 mg, about 0.81 mg, about 0.82 mg, about 0.83 mg, about 0.84 mg, about 0.85 mg, about 0.86 mg, about 0.87 mg, about 0.88 mg, about 0.89 mg, about 0.90 mg, about 0.91 mg, about 0.92 mg, about 0.93 mg, about 0.94 mg or about 0.95 mg calcium as a complex. In some embodiments, the supplement comprises about 10 mg of vitamin B5 and about 0.84 mg calcium as a complex.
In some embodiments, the supplement comprises magnesium sulfate
(MgS04). In some embodiments, the supplement comprises between about 0 mg and 350 mg of magnesium sulfate. In some embodiments, the supplement comprises about 6.0 mg, about 6.1 mg, about 6.2 mg, about 6.3 mg, about 6.4 mg about 6.5 mg, about 6.6 mg, about 6.7 mg, about 6.8 mg, about 6.9 mg, about 7.0 mg, about 7.1 mg, about 7.2 mg, about 7.3 mg, about 7.4 mg about 7.5 mg, about 7.6 mg, about 7.7 mg, about 7.8 mg, about 7.9 mg, or about 8.0 mg of magnesium sulfate. In some embodiments, the supplement comprises about 6.9 mg of magnesium sulfate.
In some embodiments, the supplement comprises zinc, such as zinc sulfate. In some embodiments, the supplement comprises between about 0 mg and 40 mg of zinc. In some embodiments, the supplement comprises between about 0 mg and 25 mg of zinc. In some embodiments, the supplement comprises about 17.0 mg, about
17.1 mg, about 17.2 mg, about 17.3 mg, about 17.4 mg about 17.5 mg, about 17.6 mg, about 17.7 mg, about 17.8 mg, about 17.9 mg, about 18.0 mg, about 18.1 mg, about
18.2 mg, about 18.3 mg, about 18.4 mg about 18.5 mg, about 18.6 mg, about 18.7 mg, about 18.8 mg, about 18.9 mg, or about 19.0 mg of zinc. In some embodiments, the supplement comprises about 18.2 mg of zinc.
In some embodiments, the supplement comprises copper, such as cupric sulfate. In some embodiments, the supplement comprises between about 0 mg and 10 mg of copper.
In some embodiments, the supplement comprises between about 0 mg and 2 mg of copper. In some embodiments, the supplement comprises about 0.1 mg, about 0.2 mg, about 0.3 mg, about 10.4 mg about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, or about 1.9 mg of copper. In some embodiments, the supplement comprises about 0.8 mg of copper.
In some embodiments, the supplement comprises manganese sulfate
(MnS04(H20). In some embodiments, the supplement comprises between about 0 mg and 1 1 mg of manganese sulfate. In some embodiments, the supplement comprises between about 0 mg and 5 mg of manganese sulfate. In some embodiments, the supplement comprises about 0.1 mg, about 0.2 mg, about 0.3 mg, about 10.4 mg about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 0.9 mg, about 1.0 mg, about 1.1 mg, about 1.2 mg, about 1.3 mg, about 1.4 mg about 1.5 mg, about 1.6 mg, about 1.7 mg, about 1.8 mg, about 1.9 mg, or about 2.0 mg of manganese sulfate. In some embodiments, the supplement comprises about 1.3 mg of manganese sulfate.
In some embodiments, other optional ingredients can be added to the prenatal dietary supplement of the presently disclosed subject matter. These include, but are not limited to carotenoids, such as lutein, a-carotene, β-carotene, zeaxanthin, and cryptoxanthin; polyphenols, such as tannins, lignins, and flavonoids; other vitamins; other minerals; amino acids; fruit extracts; vegetable extracts; preservatives;
sweeteners; flavorings, and colorants. Other examples of optional ingredients include, but are not limited to, vitamin A (e.g., between about 4000 IU and 8150 IU and/or between about 77 μg and 3 mg), vitamin D3 (e.g., between about 400 IU and 1000 IU), vitamin E (e.g., between about 30 μg and 150 mg), vitamin K (1 and 2; e.g., between about 11 IU and 200 IU and/or between about 9 μg and 900 μg), iron (e.g., between about 18 μg and 50 μg), iodine (e.g., kelp; e.g., between about 50 μg and 150 μg), selenium (e.g., between about 35 μg and 200 μg), chromium (e.g., between about 30 μg and 200 μg), molybdenum (e.g., between about 25 μg and 100 μg), biotin (e.g., between about 3 μg and 30 μg), potassium (e.g., between about 6 mg and 10 mg),
choline (e.g., from soy lecithin; e.g., between about 45 μg and 3.5 mg), inositol (e.g., between about 10 mg and 75 mg), omega-3 fatty acids (e.g., between about 65 and 500 mg), omega-5 fatty acids (e.g., between about 0.1 mg and 10 mg), omega-6 fatty acids (e.g., between about 14 mg and 1400 mg), omega-7 fatty acids (e.g., between about 10 mg and 1000 mg), omega-9 fatty acids (e.g., between about 66 mg and 6600 mg), PABA (para amino benzoic acid; e.g., between about 6.9 mg and 690 mg), rutin (e.g., between about 0.5 mg and 50 mg), sunflower lecithin (e.g., soy free; e.g., between about 15 mg and 1500 mg), boron (e.g., between about 50 mg and 5000 mg), and spirulina (e.g., organic; e.g. between about 30 mg and 3000 mg).The prenatal dietary supplement of the presently disclosed subject matter is formulated to maximize bioavailability of fluoride. In some embodiments, the supplement is formulated for administration on an empty stomach. In some embodiments, the supplement is formulated for administration to a subject that has previously ingested a liquid, such as water. In some embodiments, the supplement is formulated for administration after the subject drinks up to about 4 cups of water prior to taking the supplement. In some embodiments, the supplement is formulated for administration along with about 0.5 cups (4 ounces) of water. In some embodiments, the supplement is formulated for administration along with about 5 ounces of water. In some embodiments, the supplement is formulated for administration along with about 6 ounces of water. In some embodiments, the supplement is formulated for administration along with about 7 ounces of water. In some embodiments, the supplement is formulated for administration along with about 8 ounces of water. In some embodiments, the supplement is formulated for administration along with about 10 ounces, about 12 ounces, about 14 ounces, about 16 ounces, about 20 ounces, about 24 ounces, or more of water. In some embodiments, the supplement is formulated for administration at least 3 or at least 4 hours before consumption of a food, beverage, or other supplement comprising calcium. In some embodiments, the supplement is formulated for administration at least 1 hour after consumption of a food, beverage, or other supplement comprising calcium. In some embodiments, the supplement is formulated for administration at least approximately 6 hours before or after consumption of a food, beverage, or other supplementcomprising calcium. In some embodiments, the supplement is formulated for administration at night. In some
embodiments, the supplement is formulated for administration once during a 24 hour period. In some embodiments, the supplement is formulated for administration during the second and/or third trimester of pregnancy.
As used herein, the term "microbiome" refers to the totality of microbes, such as bacteria, fungi, and protists, and their genetic elements or genomes in a defined environment, e.g. within the oral cavity, genital tract, and/or gastrointestinal tract of a host. As used herein, the term "natural microbiome" refers to the microbiome of a subject before administration of a presently disclosed supplement. "Natural microbiome" may also refer to the microbiome of a subject that is not given a presently disclosed supplement. Microbiomes can be investigated or monitored using rapid DNA sequencing techniques, such as by sequencing 16S rRNA. In some embodiments, in order to sequence microbiome DNA (target DNA), it is desirable to remove contaminating mammalian genomic DNA (non-target DNA) from a DNA mixture obtained from a biological sample.
In some embodiments, the biological sample may be taken from saliva, mucosa, blood, tissue, stool, urine, oral rinses, and oral swabs, for example. In some embodiments, the relative distribution of taxonomic groups based on 16S rRNA sequence data is used to identify and characterize the microbial flora associated with the human body. In some embodiments, the microbiome may be monitored by identifying bacterial taxa, bacterial metabolic products, and/or proteins in a biological sample. In some embodiments, the microbiome is monitored by an analysis of amplification products of DNA and/or RNA of microflora, e.g. based on an analysis of amplification products of genes coding for one or more of: small subunit rRNA, intervening transcribed spacer, and large subunit rRNA. In some embodiments, the microbiome is monitored by assaying the mRNA composition of a biological sample.
In some embodiments, the distribution of microbial families within the microbiome is determined. In some embodiments, characterization may be carried to more detailed levels, e.g. to the level of genus and/or species, and/or to the level of strain or variation (e.g. variants) within a species, if desired (including the presence or absence of various genetic elements such as genes, the presence or absence of plasmids, etc.). Alternatively, higher taxanomic designations can be used such as Phyla, Class, or Order. The objective is to identify which microbes (usually bacteria,
but also optionally fungi, such as yeasts, protists, etc.) are present in the sample from the individual and the relative distributions of those microbes, e.g. expressed as a percentage of the total number of microbes that are present, thereby establishing a microfloral pattern or signature for the subj ect being tested, e.g. for the region of the oral cavity, genital tract, and/or gastrointestinal tract that has been sampled, or for the type of sample that is analyzed.
In some embodiments, when many taxa are being considered, the overall partem of microflora is assessed, i.e. not only are particular taxa identified, but the percentage of each constituent taxon is taken in account, in comparison to all taxa that are detected and, usually, or optionally, to each other. Those of skill in the art will recognize that many possible ways of expressing or compiling such data exist. For example, a "pie chart" format may be used to depict a microfloral signature; or the relationships may be expressed numerically or graphically as ratios or percentages of all taxa detected, etc. Further, the data may be manipulated so that only selected subsets of the taxa are considered (e.g. key indicators with strong positive correlations). Data may be expressed, e.g. as a percentage of the total number of microbes detected, or as a weight percentage, etc. In some embodiments, a nonparametric multivariate test such as Metastats, Analysis of Similarity, Principle Component Analysis, Non-Parametric MANOVA (Kruskal-Wallace) etc. can be used to associate a change in microbiome from a subject before the prenatal dietary supplement is administered to the microbiome of the subject after the prenatal dietary supplement has been administered.
In some embodiments, there are changes in the microbiota composition. In some embodiments, there are changes in the total number of bacteria in the microbiome. In some embodiments, there are changes in both the microbiota composition and the total number of bacteria in the microbiome. In some
embodiments, there are changes in the total number of at least one type of anaerobic bacteria. In some embodiments, there are changes in the total number of at least one type of anaerobic, gram-negative bacteria. In some embodiments, there are changes in the total number of at least one type of bacteria selected from the group consisting of anaerobic gram-negative bacteria, such as Porphyromonas gingivalis,
Campylobacter rectus, Tannerella forsythensis, Treponema denticola, Fusobacterium
nucleatum, Peptostreptococcus micros, Prevotella intermedia, and Prevotella nigrescence. In some embodiments, there are changes in the total number of
Porphyromonas gingivalis. In some embodiments, there are changes in the total number of Campylobacter rectus. In some embodiments, there are changes in the total number of Tannerella forsythensis. In some embodiments, there are changes in the total number of Treponema denticola. In some embodiments, there are changes in the total number of Fusobacterium nucleatum. In some embodiments, there are changes in the total number of Peptostreptococcus micros. In some embodiments, there are changes in the total number of Prevotella intermedia. In some
embodiments, there are changes in the total number of Prevotella nigrescence. As used herein, the term "anaerobic bacteria" refers to bacteria that do not require normal levels of oxygen for survival and/or growth. As used herein, the term "gram-negative bacteria" refer to those classes of bacteria that do not retain the crystal violet stain. As used herein, the term "bacteremia" refers to the presence of bacteria in the blood. "Transient bacteremia" refers to bacteremia that is not persistent. Bacteremia in a pregnant woman can affect the woman as well as the fetus. As used herein, an "ascending infection" is an infection in which the organism causing the infection contaminates the amniotic fluid.
One of skill in the art will recognize that agents for use within the
compositions, kits and methods of the presently disclosed subject matter include the pharmaceutically acceptable salts of the compounds described above. The term "pharmaceutically acceptable salts" is meant to include salts of active compounds, which are prepared with relatively nontoxic acids or bases, depending on the particular substituent moieties found on the compounds described herein.
Certain agents for use within the methods of the presently disclosed subj ect matter can exist in unsolvated forms, as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are encompassed within the scope of the present disclosure. Certain agents for use within the methods of the presently disclosed subject matter may exist in multiple crystalline or amorphous forms.
The presently disclosed prenatal dietary supplement can be administered using a variety of methods known in the art. The administering can be carried out by, for
example, intravenous infusion; inj ection by intravenous, intraperitoneal, intracerebral, intramuscular, intraocular, intraarterial or intralesional routes; or topical or oral application. In some particular embodiments, as described herein, the presently disclosed supplements are administered orally.
In some embodiments, the prenatal dietary supplement is in the form of a tablet. In some embodiments, the prenatal dietary supplement is in the form of a pill. In some embodiments, the prenatal dietary supplement is in the form of a capsule. In some embodiments, the prenatal dietary supplement is in the form of a liquid or liquid concentrate. In some embodiments, the prenatal dietary supplement is in the form of a powder.
Agents for use within the compositions, kits, and methods of the presently disclosed subject matter can be manufactured in a manner known in the art, e.g. by means of conventional mixing, dissolving, granulating, dragee-making, levitating, emulsifying, encapsulating, entrapping or lyophilizing processes.
More particularly, agents within the compositions, kits, and methods of the presently disclosed subject matter for oral use can be obtained through combination of active compounds with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients include, but are not limited to, carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethyl cellulose; and gums including arabic and tragacanth; and proteins, such as gelatin and collagen; and polyvinylpyrrolidone (PVP:povidone). If desired, disintegrating or solubilizing agents, such as cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, also can be added to the compositions.
Dragee cores are provided with suitable coatings, such as concentrated sugar solutions, which also can contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol (PEG), and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments can be added to the tablets or dragee coatings for product identification or to characterize the quantity
of active compound, e.g., dosage, or different combinations of active compound doses.
Pharmaceutical compositions suitable for oral administration include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, e.g., a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain active ingredients admixed with a filler or binder, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols (PEGs), with or without stabilizers. Stabilizers can be added as warranted.
In some embodiments, the agents for use within the compositions, kits, and methods of the presently disclosed subject matter can be administered by rechargeable or biodegradable devices. For example, a variety of slow-release polymeric devices have been developed and tested in vivo for the controlled delivery of drugs, including proteinacious biopharmaceuticals. Suitable examples of sustained release
preparations include semipermeable polymer matrices in the form of shaped articles, e.g., films or microcapsules. Sustained release matrices include polyesters, hydrogels, polylactides (U.S. Patent No. 3,773,919; EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al, Biopolymers 22:547, 1983), poly (2- hydroxyethyl-methacrylate) (Langer et al, J. Biomed. Mater. Res. 15: 167, 1981 ;
Langer, Chem. Tech. 12:98, 1982), ethylene vinyl acetate (Langer et al, Id), or poly- D-(-)-3-hydroxybutyric acid (EP 133,988A). Sustained release compositions also include liposomally entrapped compounds, which can be prepared by methods known per se (Epstein et al., Proc. Natl. Acad. Sci. U.S.A. 82:3688, 1985; Hwang et al., Proc. Natl. Acad. Sci. U.S.A. 77:4030, 1980; U.S. Patent Nos. 4,485,045 and 4,544,545; and EP 102,324 A). Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamelar type in which the lipid content is greater than about 30 mol % cholesterol, the selected proportion being adjusted for the optimal therapy. Such materials can comprise an implant, for example, for sustained release of the presently disclosed compounds, which, in some embodiments, can be implanted at a particular, pre-determined target site.
Pharmaceutical compositions for parenteral administration include aqueous solutions of active compounds. For injection, the presently disclosed pharmaceutical compositions can be formulated in aqueous solutions, for example, in some embodiments, in physiologically compatible buffers, such as Hank's solution, Ringer' solution, or physiologically buffered saline. Aqueous injection suspensions can contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Optionally, the suspension also can contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
For nasal or transmucosal administration generally, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
For inhalation delivery, agents for use within the methods of the presently disclosed subject matter also can be formulated by methods known to those of skill in the art, and may include, for example, but not limited to, examples of solubilizing, diluting, or dispersing substances such as, saline, preservatives, such as benzyl alcohol, absorption promoters, and fluorocarbons.
Additional ingredients can be added to compositions for topical
administration, as long as such ingredients are pharmaceutically acceptable and not deleterious to the epithelial cells or their function. Further, such additional ingredients should not adversely affect the epithelial penetration efficiency of the composition, and should not cause deterioration in the stability of the composition. For example, fragrances, opacifiers, antioxidants, gelling agents, stabilizers, surfactants, emollients, coloring agents, preservatives, buffering agents, and the like can be present. The pH of the presently disclosed topical composition can be adjusted to a physiologically acceptable range of from about 6.0 to about 9.0 by adding buffering agents thereto such that the composition is physiologically compatible with a subject's skin.
Regardless of the route of administration selected, agents for use within the methods of the presently disclosed subject matter, which may be used in a suitable
hydrated form, and/or the pharmaceutical compositions are formulated into pharmaceutically acceptable dosage forms such as described below or by other conventional methods known to those of skill in the art. KITS COMPRISING PRENATAL DIETARY SUPPLEMENTS
The presently disclosed subject matter also relates to kits for practicing the methods of the presently disclosed subject matter. In general, a presently disclosed kit contains some or all of the components, reagents, supplies, and the like to practice a method according to the presently disclosed subject matter. In some embodiments, the term "kit" refers to any intended any article of manufacture (e.g., a package or a container) comprising at least one prenatal dietary supplement and a set of particular instructions for practicing the methods of the presently disclosed subject matter. The kit can be packaged in a divided or undivided container, such as a carton, bottle, ampule, tube, etc. The presently disclosed supplements can be packaged in dried, lyophilized, or liquid form. In some embodiments, the supplements are packaged in pill, capsule, or tablet form.
In some embodiments, the presently disclosed subject matter provides a kit comprising: (a) a prenatal dietary supplement described herein; and (b) a package insert or label with directions to administer the prenatal dietary supplement to a pregnant woman during the second and/or third trimesters of her pregnancy.
In some embodiments, the directions instruct the pregnant woman to take the prenatal dietary supplement on an empty stomach or after drinking a liquid, such as water. In some embodiments, the directions instruct the pregnant woman to take the prenatal dietary supplement at night.
METHODS FOR USING A PRENATAL DIETARY SUPPLEMENT
In some embodiments, the presently disclosed methods change the natural microbiome of a pregnant woman, the method comprising administering a prenatal dietary supplement of presently disclosed subject matter to the pregnant woman. In some embodiments, by changing the natural microbiome of a pregnant woman, the presently disclosed methods protect the pregnant woman and her fetus against transient bacteremia and/or ascending infection. In some embodiments, by protecting
the pregnant woman and her fetus against transient bacteremia and/or ascending infection, the presently disclosed methods increase the length of gestation of a fetus. The prenatal dietary supplement disclosed herein may increase the length of gestation of a fetus in a pregnant woman by at least 5%, at least 10%, at least 15%, at least 20%, or at least 25% compared to the length of gestation of the fetus in the pregnant woman in the absence of supplementation with the supplement. In some
embodiments, the natural microbiome comprises a microbiome of the oral cavity, genital tract, and/or gastrointestinal tract of the pregnant woman.
In some embodiments, the methods comprise selecting a pregnant woman whose fetus is thought to need an extended length of gestation. The selection of a pregnant woman may be based on a variety of factors, such as a family history of relatives giving birth to a premature baby or giving birth to a baby before the due date even though it may be mature, and/or the pregnant woman herself giving birth previously to a baby born prematurely or born before the baby's due date. In some embodiments, the length of the gestation is expected to be increased by at least about 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, a week, two weeks, three weeks, a month, two months or more.
It is believed that the fluoride in the prenatal dietary supplement described herein aids in changing the natural microbiome of a pregnant woman. Thus, in some embodiments, the prenatal dietary supplement does not comprise compounds that reduce the bioavailability of fluoride. In addition, in some embodiments, the supplement is administered in the absence of other sources of compounds that reduce the bioavailability of fluoride, such as calcium.
Therefore, in some embodiments, the prenatal dietary supplement is administered when the pregnant woman has an empty stomach. In some
embodiments, the prenatal dietary supplement is administered when the pregnant woman has previously ingested a liquid, such as water. In some embodiments, the prenatal dietary supplement is administered with plenty of water. In some embodiments, plenty of water comprises consuming at least 8 OZ, at least 16 OZ, at least 24 OZ, at least 32 OZ, at least 48 OZ, or at least 64 OZ between about 120 minutes, 90 minutes, 60 minutes, 45 minutes, 30 minutes, or 15 minutes before and after taking the prenatal dietary supplement. In some embodiments, the supplement is
formulated for administration after the pregnant woman drinks up to about 4 cups of water prior to taking the supplement. In some embodiments, the pregnant woman is administered the supplement along with about 0.5 cups (4 ounces) of water. In some embodiments, the pregnant woman is administered the supplement at least 3 or at least 4 hours before the pregnant woman consumes a food, beverage, or other supplement comprising calcium. In some embodiments, the pregnant woman is administered the supplement at least 1 hour after the pregnant woman consumes a food, beverage, or other supplement comprising calcium. In some embodiments, the prenatal dietary supplement is administered at least approximately 6 hours before or after the pregnant woman consumes a food, beverage, or other supplement comprising calcium. In some embodiments, the pregnant woman is instructed not to drink milk or consume any other food, beverage, or other supplement comprising calcium at least 3 or at least 4 hours before taking, or at least 1 hour after taking, the prenatal dietary supplement.
In some embodiments, the prenatal dietary supplement is administered at night when other sources of calcium are not taken. In some embodiments, the prenatal dietary supplement is administered once every 24 hours. In some embodiments, the prenatal dietary supplement is administered during the second and/or third trimester of pregnancy. In some embodiments, the prenatal dietary supplement is administered (e.g., once daily at nighttime on an empty stomach with plenty of water) from the 12th week of pregnancy until the pregnant woman gives birth.
In some embodiments, the prenatal dietary supplement is administered once every 24 hours at nighttime with plenty of water when other sources of calcium are not taken.
The subject treated by the presently disclosed methods in their many embodiments is desirably a human pregnant woman, although it is to be understood that the methods described herein are effective with respect to all female vertebrate species, which are intended to be included in the term "subject." Accordingly, a "subject" can include a female human subject for medical purposes, such as for the treatment of an existing disease, disorder, condition or the prophylactic treatment for preventing the onset of a disease, disorder, or condition or a female animal subject for medical, veterinary purposes, or developmental purposes. Suitable animal subjects
include mammals including, but not limited to, primates, e.g., humans, monkeys, apes, gibbons, chimpanzees, orangutans, macaques and the like; bovines, e.g., cattle, oxen, and the like; ovines, e.g., sheep and the like; caprines, e.g., goats and the like; porcines, e.g., pigs, hogs, and the like; equines, e.g., horses, donkeys, zebras, and the like; felines, including wild and domestic cats; canines, including dogs; lagomorphs, including rabbits, hares, and the like; and rodents, including mice, rats, guinea pigs, and the like. An animal may be a transgenic animal.
GENERAL DEFINITIONS
Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this presently described subject matter belongs.
Following long-standing patent law convention, the terms "a," "an," and "the" refer to "one or more" when used in this application, including the claims. Thus, for example, reference to "a subject" includes a plurality of subjects, unless the context clearly is to the contrary (e.g., a plurality of subjects), and so forth.
Throughout this specification and the claims, the terms "comprise,"
"comprises," and "comprising" are used in a non-exclusive sense, except where the context requires otherwise. Likewise, the term "include" and its grammatical variants are intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that can be substituted or added to the listed items.
For the purposes of this specification and appended claims, unless otherwise indicated, all numbers expressing amounts, sizes, dimensions, proportions, shapes, formulations, parameters, percentages, parameters, quantities, characteristics, and other numerical values used in the specification and claims, are to be understood as being modified in all instances by the term "about" even though the term "about" may not expressly appear with the value, amount or range. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are not and need not be exact, but may be approximate and/or larger or smaller as desired, reflecting tolerances, conversion factors, rounding off,
measurement error and the like, and other factors known to those of skill in the art depending on the desired properties sought to be obtained by the presently disclosed subject matter. For example, the term "about," when referring to a value can be meant to encompass variations of, in some embodiments, ± 100% in some embodiments ± 50%, in some embodiments ± 20%, in some embodiments ± 10%, in some embodiments ± 5%, in some embodiments ±1 %, in some embodiments ± 0.5%, and in some embodiments ± 0.1 % from the specified amount, as such variations are appropriate to perform the disclosed methods or employ the disclosed compositions.
Further, the term "about" when used in connection with one or more numbers or numerical ranges, should be understood to refer to all such numbers, including all numbers in a range and modifies that range by extending the boundaries above and below the numerical values set forth. The recitation of numerical ranges by endpoints includes all numbers, e.g., whole integers, including fractions thereof, subsumed within that range (for example, the recitation of 1 to 5 includes 1 , 2, 3, 4, and 5, as well as fractions thereof, e.g., 1.5, 2.25, 3.75, 4.1, and the like) and any range within that range.
EXAMPLES
The following Examples have been included to provide guidance to one of ordinary skill in the art for practicing representative embodiments of the presently disclosed subject matter. In light of the present disclosure and the general level of skill in the art, those of skill can appreciate that the following Examples are intended to be exemplary only and that numerous changes, modifications, and alterations can be employed without departing from the scope of the presently disclosed subject matter. The following Examples are offered by way of illustration and not by way of limitation.
EXAMPLE 1
Exemplary Ranges of Amounts of Compounds in a Prenatal Dietary Supplement In this Example, some exemplary ranges of amounts of compounds in an embodiment of a presently disclosed dietary supplement are shown in Table 1.
Table 1. Ranges of amounts of compounds
EXAMPLE 2
Exemplary Embodiment of a Prenatal Dietary Supplement In this Example, some exemplary amounts of compounds in an embodiment of a presently disclosed dietary supplement are shown in Table 2.
Table 2. Amounts of compounds in an exemplary embodiment
REFERENCES
All publications, patent applications, patents, and other references mentioned in the specification are indicative of the level of those skilled in the art to which the presently disclosed subject matter pertains. All publications, patent applications, patents, and other references are herein incorporated by reference to the same extent as if each individual publication, patent application, patent, and other reference was specifically and individually indicated to be incorporated by reference. It will be understood that, although a number of patent applications, patents, and other
references are referred to herein, such reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art.
Although the foregoing subject matter has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be understood by those skilled in the art that certain changes and modifications can be practiced within the scope of the appended claims.
Claims
1. A prenatal dietary supplement comprising a source of fluoride in an amount effective to provide at least about 3 mg of bioavailable fluoride.
2. The prenatal dietary supplement of claim 1 , wherein the source of fluoride is in an amount effective to provide between about 3 mg and 5 mg of bioavailable fluoride.
3. The prenatal dietary supplement of claim 1, wherein the amount effective comprises between about 6 mg and 1 1 mg of the source of fluoride.
4. The prenatal dietary supplement of claim 3, wherein the amount effective comprises about 6.6 mg of the source of fluoride.
5. The prenatal dietary supplement of any one of claims 1 -4, wherein the supplement comprises decreased amounts of at least one cation that complexes with fluoride to reduce bioavailability of fluoride.
6. The prenatal dietary supplement of claim 5, wherein the at least one cation is selected from the group consisting of calcium and magnesium.
7. The prenatal dietary supplement of any one of claims 1-6, wherein the supplement comprises a source of calcium that does not complex with fluoride to reduce the bioavailability of fluoride.
8. The prenatal dietary supplement of claim 7, wherein the source of calcium comprises calcium complexed to a vitamin.
9. The prenatal dietary supplement of claim 8, wherein the source of calcium comprises calcium complexed to vitamin B5.
10. The prenatal dietary supplement of claim 9, wherein the supplement comprises about 10 mg of vitamin B5 and about 0.84 mg calcium as a complex.
11. The prenatal dietary supplement of any one of claims 1-10, wherein the source of fluoride is selected from the group consisting of sodium fluoride, sodium monofiuorophosphate, stannous fluoride, and combinations thereof.
12. The prenatal dietary supplement of any one of claims 1-10, wherein the source of fluoride comprises sodium fluoride.
13. The prenatal dietary supplement of any one of claims 1-12, further comprising between about 0 mg and about 2000 mg of vitamin C.
14. The prenatal dietary supplement of any one of claims 1-13, further comprising about 200 mg of vitamin C.
15. The prenatal dietary supplement of any one of claims 1-14, further comprising between about 0 mg and 100 mg of vitamin Bi.
16. The prenatal dietary supplement of any one of claims 1-15, further comprising about 10 mg of vitamin Bi.
17. The prenatal dietary supplement of any one of claims 1-16, further comprising between about 0 mg and 60 mg of vitamin B2.
18. The prenatal dietary supplement of any one of claims 1-17, further comprising about 6 mg of vitamin B2.
19. The prenatal dietary supplement of any one of claims 1-18, further comprising between about 0 mg and 35 mg of vitamin B3.
20. The prenatal dietary supplement of any one of claims 1-19, further comprising about 30 mg of vitamin B3.
21. The prenatal dietary supplement of any one of claims 1-20, further comprising between about 0 mg and 50 mg of vitamin Be.
22. The prenatal dietary supplement of any one of claims 1-21, further comprising about 5 mg of vitamin Be.
23. The prenatal dietary supplement of any one of claims 1-22, further comprising between about 0 mg and 1 mg of folic acid.
24. The prenatal dietary supplement of any one of claims 1-23, further comprising about 1 mg of folic acid.
25. The prenatal dietary supplement of any one of claims 1-24, further comprising between about 0 μg and 150 μg of vitamin B12.
26. The prenatal dietary supplement of any one of claims 1-25, further comprising about 15 μg of vitamin B12.
27. The prenatal dietary supplement of any one of claims 1-26, further comprising between about 0 mg and 100 mg of vitamin B5.
28. The prenatal dietary supplement of any one of claims 1-27, further comprising about 10 mg of vitamin B5.
29. The prenatal dietary supplement of any one of claims 1-28, further comprising between about 0 mg and 69 mg of magnesium sulfate.
30. The prenatal dietary supplement of any one of claims 1-29, further comprising about 6.9 mg of magnesium sulfate.
31. The prenatal dietary supplement of any one of claims 1-30, further comprising between about 0 mg and 40 mg of zinc.
32. The prenatal dietary supplement of any one of claims 1-31, further comprising about 18.2 mg of zinc.
33. The prenatal dietary supplement of any one of claims 1-32, further comprising between about 0 mg and 10 mg of copper.
34. The prenatal dietary supplement of any one of claims 1-33, further comprising about 0.8 mg of copper.
35. The prenatal dietary supplement of any one of claims 1-34, further comprising between about 0 mg and 13 mg of manganese sulfate.
36. The prenatal dietary supplement of any one of claims 1-35, further comprising about 1.3 mg of manganese sulfate.
37. The prenatal dietary supplement of any one of claims 1-36, wherein the supplement extends the length of gestation of a fetus when the supplement is administered to a pregnant woman during the second and third trimesters of pregnancy.
38. The prenatal dietary supplement of any one of claims 1-37, wherein the supplement changes the natural microbiome of a pregnant woman when administered to a pregnant woman during the second and third trimesters of pregnancy.
39. The prenatal dietary supplement of any one of claims 1-38, wherein the supplement protects a pregnant woman and her fetus against transient bacteremia and ascending infection when the supplement is administered to the pregnant woman during the second and third trimesters of pregnancy.
40. The prenatal dietary supplement of any one of claims 1-39, wherein the supplement is formulated for administration on an empty stomach or after drinking water.
41. The prenatal dietary supplement of any one of claims 1-40, wherein the supplement is formulated for administration at least 3 or at least 4 hours before, or at least 1 hour after, consumption of a food, beverage, or other supplement comprising calcium.
42. The prenatal dietary supplement of any one of claims 1-41, wherein the supplement is formulated for administration at night.
43. The prenatal dietary supplement of any one of claims 1-42, wherein the supplement is formulated for administration once during a 24 hour period.
44. The prenatal dietary supplement of any one of claims 1-43, wherein the supplement is formulated for administration during the second and/or third trimester of pregnancy.
45. The prenatal dietary supplement of any one of claims 1-44, wherein the supplement comprises a form selected from the group consisting of a pill, tablet, capsule, liquid, liquid concentrate, and powder.
46. A kit comprising:
(a) a prenatal dietary supplement according to any one of claims 1-45; and
(b) a package insert or label with directions to administer the prenatal dietary supplement to a pregnant woman during the second and/or third trimesters of her pregnancy.
47. The kit of claim 46, wherein the directions instruct the pregnant woman to take the prenatal dietary supplement on an empty stomach.
48. The kit of claims 46-47, wherein the directions instruct the pregnant woman to take the prenatal dietary supplement at night.
49. A method for increasing the length of gestation of a fetus, the method comprising administering the prenatal dietary supplement of any one of claims 1-45, or kit of any one of claims 46-48, to the pregnant woman.
50. A method for changing the natural microbiome of a pregnant woman, the method comprising administering the prenatal dietary supplement of any one of claims 1-45, or kit according to any one of claims 46-48, to the pregnant woman.
51. The method of claim 50, wherein the natural microbiome comprises a microbiome of the oral cavity, genital tract, and/or gastrointestinal tract of the pregnant woman.
52. A method for protecting a pregnant woman and her fetus against transient bacteremia and/or ascending infection, the method comprising administering the prenatal dietary supplement of any one of claims 1-45, or kit according to any one of claims 46-48, to the pregnant woman.
53. The method of any one of claims 49-52, wherein the prenatal dietary supplement is administered when the pregnant woman has an empty stomach or has previously ingested water.
54. The method of any one of claims 49-53, wherein the prenatal dietary supplement is administered at least 3 or at least 4 hours before, or at least 1 hour after, the pregnant woman consumes a food, beverage, or other supplement comprising calcium.
55. The method of any one of claims 49-54, wherein the pregnant woman is instructed not to drink milk or consume any other food, beverage, or other supplement
comprising calcium at least 3 or at least 4 hours before taking, or at least 1 hour after taking, the prenatal dietary supplement.
56. The method of any one of claims 49-55, wherein the prenatal dietary supplement is administered with plenty of water.
57. The method of any one of claims 49-56, wherein the prenatal dietary supplement is administered at night.
58. The method of any one of claims 49-57, wherein the prenatal dietary supplement is administered once every 24 hours.
59. The method of any one of claims 49-58, wherein the prenatal dietary supplement is administered during the second and/or third trimester of pregnancy.
60. The method of any one of claims 49 to 59, wherein the prenatal dietary supplement is administered from the 12th week of pregnancy until the pregnant woman gives birth.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16796985.6A EP3294072A4 (en) | 2015-05-15 | 2016-05-13 | Novel fluoride prenatal dietary supplement |
US15/574,114 US20180146703A1 (en) | 2015-05-15 | 2016-05-13 | Novel fluoride prenatal dietary supplement |
US17/980,714 US20230061061A1 (en) | 2015-05-15 | 2022-11-04 | Novel fluoride prenatal dietary supplement |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562162198P | 2015-05-15 | 2015-05-15 | |
US62/162,198 | 2015-05-15 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/574,114 A-371-Of-International US20180146703A1 (en) | 2015-05-15 | 2016-05-13 | Novel fluoride prenatal dietary supplement |
US17/980,714 Continuation US20230061061A1 (en) | 2015-05-15 | 2022-11-04 | Novel fluoride prenatal dietary supplement |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016186977A1 true WO2016186977A1 (en) | 2016-11-24 |
Family
ID=57320316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2016/032243 WO2016186977A1 (en) | 2015-05-15 | 2016-05-13 | Novel fluoride prenatal dietary supplement |
Country Status (3)
Country | Link |
---|---|
US (2) | US20180146703A1 (en) |
EP (1) | EP3294072A4 (en) |
WO (1) | WO2016186977A1 (en) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0058481A1 (en) | 1981-02-16 | 1982-08-25 | Zeneca Limited | Continuous release pharmaceutical compositions |
EP0102324A2 (en) | 1982-07-29 | 1984-03-07 | Ciba-Geigy Ag | Lipids and surfactants in an aqueous medium |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0133988A2 (en) | 1983-08-02 | 1985-03-13 | Hoechst Aktiengesellschaft | Regulating peptide-containing pharmaceutical preparations with retarded release, and process for their preparation |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US20030104078A1 (en) * | 2001-03-30 | 2003-06-05 | Bridget Barrett-Reis | Method of improving the antioxidant status of an infant |
US6576253B2 (en) * | 2000-12-05 | 2003-06-10 | Pbm Pharmaceuticals, Inc. | Food bars containing nutritional supplements |
US20090317488A1 (en) * | 2006-10-03 | 2009-12-24 | Tris Pharma, Inc | Formulations Containing an Ionic Mineral-Ion Exchange Resin Complex and Uses Thereof |
WO2011150395A2 (en) * | 2010-05-28 | 2011-12-01 | Bmg Hematology Llc | Nutrient compositions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6673380B2 (en) * | 1998-11-17 | 2004-01-06 | Mcneil-Ppc, Inc. | Fortified confectionery delivery systems and methods of preparation thereof |
US6576273B2 (en) * | 2000-08-24 | 2003-06-10 | Chr. Hansen A/S | Purification process for improving total yield of curcuminoid colouring agent |
FR2857826A1 (en) * | 2003-07-25 | 2005-01-28 | United Pharmaceuticals Sa | Food product containing fluorides intended to provide controlled amounts of fluoride to pregnant women, lactating women, babies and very young children |
EP1656148A4 (en) * | 2003-08-21 | 2011-07-20 | Duchesnay Inc | Micronutrient supplement |
WO2009151457A1 (en) * | 2008-06-13 | 2009-12-17 | Sciele Pharma, Inc. | Nutritional preparations |
CN101889669B (en) * | 2010-06-24 | 2012-07-18 | 华瑞制药有限公司 | Eternal nutrition emulsion and preparation method thereof |
-
2016
- 2016-05-13 EP EP16796985.6A patent/EP3294072A4/en active Pending
- 2016-05-13 WO PCT/US2016/032243 patent/WO2016186977A1/en active Application Filing
- 2016-05-13 US US15/574,114 patent/US20180146703A1/en not_active Abandoned
-
2022
- 2022-11-04 US US17/980,714 patent/US20230061061A1/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0058481A1 (en) | 1981-02-16 | 1982-08-25 | Zeneca Limited | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
EP0102324A2 (en) | 1982-07-29 | 1984-03-07 | Ciba-Geigy Ag | Lipids and surfactants in an aqueous medium |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
EP0133988A2 (en) | 1983-08-02 | 1985-03-13 | Hoechst Aktiengesellschaft | Regulating peptide-containing pharmaceutical preparations with retarded release, and process for their preparation |
US6576253B2 (en) * | 2000-12-05 | 2003-06-10 | Pbm Pharmaceuticals, Inc. | Food bars containing nutritional supplements |
US20030104078A1 (en) * | 2001-03-30 | 2003-06-05 | Bridget Barrett-Reis | Method of improving the antioxidant status of an infant |
US20090317488A1 (en) * | 2006-10-03 | 2009-12-24 | Tris Pharma, Inc | Formulations Containing an Ionic Mineral-Ion Exchange Resin Complex and Uses Thereof |
WO2011150395A2 (en) * | 2010-05-28 | 2011-12-01 | Bmg Hematology Llc | Nutrient compositions |
Non-Patent Citations (9)
Title |
---|
"Food and Nutrition Board", 1997, INSTITUTE OF MEDICINE, article "Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride" |
EPSTEIN ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 82, 1985, pages 3688 |
HWANG ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 77, 1980, pages 4030 |
LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 |
LANGER, CHEM. TECH., vol. 12, 1982, pages 98 |
LEVERETT ET AL.: "Randomized clinical trial of the effect of prenatal fluoride supplements in preventing dental caries", CARIES RESEARCH, vol. 31, no. 3, 1997, pages 174 - 179 |
See also references of EP3294072A4 |
SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 |
ZHU, JIA-QIAO ET AL.: "Sodium fluoride disrupts DNA methylation of H19 and Peg3 imprinted genes during the early development of mouse embryo", ARCHIVES OF TOXICOLOGY, vol. 88, no. 2, 13 September 2013 (2013-09-13), pages 241 - 248, XP055332185 * |
Also Published As
Publication number | Publication date |
---|---|
US20230061061A1 (en) | 2023-03-02 |
EP3294072A4 (en) | 2019-03-13 |
US20180146703A1 (en) | 2018-05-31 |
EP3294072A1 (en) | 2018-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170007536A1 (en) | Dental Composition and Method | |
CN101239069A (en) | Application of compound capable of supplying active methyl or engaging in methyl migration | |
AU2012209285A1 (en) | Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals | |
JP2022023868A (en) | Magnesium biotinate compositions and methods of use | |
CN106255706A (en) | TATk CDKL5 fusion protein, a combination thereof thing, preparation and purposes | |
JP2021185145A (en) | Maca compositions and methods of use | |
AU2016205145A1 (en) | Methods of treating diarrhea in companion animals | |
US20230061061A1 (en) | Novel fluoride prenatal dietary supplement | |
AU2017336291B2 (en) | Omega 3 fatty acids, no releasing compound and vitamin B12 as neuroprotectant in patients with no dementia | |
WO2015184101A1 (en) | Methods of treating diarrhea in neonatal and young non-human animals | |
US10668027B1 (en) | Method of treating Acanthamoeba infection using allopurinol | |
EP3388061A1 (en) | Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia | |
US9655901B1 (en) | Methods of treating Nfa-1 organism infection using allopurinol | |
RU2813776C1 (en) | Method of treating salmonellosis in young cattle | |
RU2760674C1 (en) | Use of preparations of polyscias filicifolia plant or its fragments for treatment of elementoses and their consequences | |
WO2023282283A1 (en) | Composition for improving oral environment | |
Nouri | Encapsulated organic acids as a safe alternative or synergistic compound with anticoccidials for more effective control of coccidiosis in Eimeria-challenged broilers | |
WO2017106074A1 (en) | Methods of treating diarrhea in pre-weaned, neonatal and young non-human animals | |
CN117694543A (en) | Composition for improving joints and improving mobility and application thereof | |
Zalubovska et al. | Drug influence on laboratory indices | |
KR20220113858A (en) | Light meal typed pet nutrient having a shape of red ginseng | |
JP2024510726A (en) | Method for reducing the number of Fusobacteria in intestinal flora | |
CA2673636C (en) | Dental composition and method | |
WO2009123457A2 (en) | Compositions and methods for treating sweet itch | |
JP2006335656A (en) | Composition for adjusting th1/th2 bioreaction imbalance |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16796985 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15574114 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016796985 Country of ref document: EP |